MRP1/ABCC1 Antibody (Rabbit mAb) [M22C19]

Catalog No.: F4915

    Application: Reactivity:
    • Lane 1: A549, Lane 2: HepG2, Lane 3: K562, Lane 4: NIH/3T3
    1/

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    キーポイント

    WB
    SDS-PAGE の分離ゲルの推奨濃度:5%

    使用情報

    Dilution
    1:1000
    1:30
    1:1000
    1:600
    Application
    WB, IP, IHC, FCM
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Mouse, Human
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    172 kDa 172 kDa, 120-250 kDa
    *なぜ予測分子量と実際の分子量が異なるのか?
    下記の原因により、実際の分子量が予測と異なる:タンパク質の翻訳後修飾(リン酸化/糖鎖付加),スプライシングバリアント,イソフォーム,相対的な電荷,ポリマー。
    ポジティブコントロール Human lung cancer tissue; Human lung tissue; Mouse stomach tissue; MCF7 cells; A549 cells; DU 145 cells; HeLa cells; NIH/3T3 cells; HepG2 cells; K-562 cells
    ネガティブコントロール Mouse liver; 293 cells

    プロトコール

    WB
    Experimental Protocol:
     
    Sample preparation
    1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature or lyse it by sonication on ice, then incubate on ice for 30 minutes.
    2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
    5. Remove a small volume of lysate to determine the protein concentration;
    6. Add protein loading buffer to the 20 μL sample, and keep it on ice for immediate use; or determine the optimal denaturation conditions by boiling the sample at a temperature gradient (e.g., 37°C, 50°C, 70°C, 90°C, and 100°C). Cool the sample on ice and centrifuge for 5 min.
     
    Electrophoretic separation
    1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 5%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
    2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
     
    Transfer membrane
    1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
    2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
    3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
    4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
    Recommended conditions for wet transfer: 200 mA, 120 min.
    ( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
     
    Block
    1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
    2. Incubate the film in the blocking solution for 1 hour at room temperature;
    3. Wash the film with TBST for 3 times, 5 minutes each time.
     
    Antibody incubation
    1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:1000), gently shake and incubate with the film at 4°C overnight;
    2. Wash the film with TBST 3 times, 5 minutes each time;
    3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
    4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
     
    Antibody staining
    1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
    2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.
    IHC
    Experimental Protocol:
     
    Deparaffinization/Rehydration
    1. Deparaffinize/hydrate sections:
    2. Incubate sections in three washes of xylene for 5 min each.
    3. Incubate sections in two washes of 100% ethanol for 10 min each.
    4. Incubate sections in two washes of 95% ethanol for 10 min each.
    5. Wash sections two times in dH2O for 5 min each.
    6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min.
     
    Staining
    1. Wash sections in dH2O three times for 5 min each.
    2. Incubate sections in 3% hydrogen peroxide for 10 min.
    3. Wash sections in dH2O two times for 5 min each.
    4. Wash sections in wash buffer for 5 min.
    5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature.
    6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C.
    7. Remove antibody solution and wash sections with wash buffer three times for 5 min each.
    8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature.
    9. Wash sections three times with wash buffer for 5 min each.
    10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use.
    11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity.
    12. Immerse slides in dH2O.
    13. If desired, counterstain sections with hematoxylin.
    14. Wash sections in dH2O two times for 5 min each.
    15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each.
    16. Mount sections with coverslips and mounting medium.
     

    Datasheet & SDS

    生物学的記述

    Specificity
    MRP1/ABCC1 Antibody (Rabbit mAb) [M22C19] detects endogenous levels of total MRP1/ABCC1 protein.
    タンパク質の局在
    細胞膜、細胞内膜系
    Uniprot ID
    P33527
    Clone
    M22C19
    Synonym(s)
    MRP, MRP1, ABCC1, Multidrug resistance-associated protein 1, ATP-binding cassette sub-family C member 1, Leukotriene C(4) transporter, LTC4 transporter
    Background
    MRP1, also termed ABCC1, is a full transporter of the ATP‑binding cassette C subfamily that resides predominantly in the plasma membrane and functions as a multispecific organic anion efflux pump for endogenous metabolites, conjugated lipids, and a wide range of xenobiotics, including many anticancer drugs. The protein comprises three membrane‑spanning domains with 17 transmembrane helices and two cytosolic nucleotide‑binding domains; the extra N‑terminal transmembrane bundle contributes to correct targeting and surface stability, while the canonical core transmembrane domains form a bipartite substrate‑binding cavity that couples ATP binding and hydrolysis to large conformational changes that alternate substrate access between the cytoplasmic and extracellular sides. MRP1 recognizes and transports lipophilic anionic substrates with particular preference for glutathione (GSH) conjugates and GSH‑dependent complexes, including leukotriene C4, oxidized glutathione, estradiol‑17β‑glucuronide, bilirubin, sulfated bile acids, and many drug–GSH pairs, and it also transports GSH‑independent substrates such as methotrexate and selected cyclic dinucleotides. Cryo‑EM analyses show that ABCC1 uses a plastic binding pocket that accommodates GSH conjugates, bimolecular GSH–substrate pairs, and non‑GSH ligands, and that ATP binding and hydrolysis drive transitions through substrate‑loaded, pre‑release, and post‑release states with sequential nucleotide release from the two nucleotide‑binding sites, which resets the transporter for further cycles. MRP1 is widely expressed in barrier and detoxification tissues, including lung, intestine, liver, testis, placenta, blood–brain barrier, and hematopoietic cells, where basolateral localization in polarized epithelia and high expression at the blood–brain and blood–placenta interfaces support export of organic anions and xenobiotics toward blood or maternal circulation and contribute to tissue protection from toxic compounds and lipid peroxidation products. The transporter participates in glutathione and eicosanoid pathways by exporting GSH conjugates and cysteinyl leukotrienes, influences cellular redox homeostasis by controlling levels of oxidized glutathione and 4‑hydroxynonenal adducts, and exports immunostimulatory cyclic GMP–AMP to propagate cGAS–STING–dependent innate immune signaling between cells. In oncology, MRP1 confers multidrug resistance by reducing intracellular accumulation of anthracyclines, vinca alkaloids, epipodophyllotoxins, camptothecin derivatives, and several targeted agents, and high ABCC1 expression associates with poor response and adverse prognosis in cancers such as lung, breast, prostate tumors, and neuroblastoma, where it often coincides with other transporters including P‑gp.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください